B

Bio-FD&C Co Ltd
KOSDAQ:251120

Watchlist Manager
Bio-FD&C Co Ltd
KOSDAQ:251120
Watchlist
Price: 14 790 KRW 0.07% Market Closed
Market Cap: 128.7B KRW
Section:
 

Relative Value

The Relative Value of one Bio-FD&C Co Ltd stock under the Base Case scenario is 17 792.6 KRW. Compared to the current market price of 14 790 KRW, Bio-FD&C Co Ltd is Undervalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
17 792.6 KRW
Undervaluation 17%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

6.7
P/S
P/S
Price to Sales
6.7
vs History
83
vs Industry
51
Median 3Y
7.5
Median 5Y
7.8
Industry
8.2
Forward
6.8
More Details
17.8
P/E
P/E
Price to Earnings
17.8
vs History
93
vs Industry
7
Median 3Y
24.4
Median 5Y
25.2
Industry
24.2
Forward
18.5
More Details
16.4
P/OCF
P/OCF
Price to OCF
16.4
vs History
93
vs Industry
10
Median 3Y
20.1
Median 5Y
21
Industry
23
More Details
23.1
P/FCFE
P/FCFE
Price to FCFE
23.1
vs History
83
vs Industry
7
Median 3Y
32.3
Median 5Y
32.3
Industry
25.5
More Details
1.9
P/B
P/B
Price to Book Value
1.9
vs History
75
vs Industry
42
Median 3Y
2.1
Median 5Y
2.2
Industry
3.3
More Details
4.3
EV/S
EV/S
Enterprise Value to Sales
4.3
vs History
81
vs Industry
53
Median 3Y
5
Median 5Y
5.3
Industry
8.6
Forward
4.3
More Details
6.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.1
vs History
77
vs Industry
49
Median 3Y
7.2
Median 5Y
7.6
Industry
10.5
More Details
10.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.2
vs History
85
vs Industry
10
Median 3Y
12.3
Median 5Y
13.8
Industry
6.1
Forward
10.6
More Details
12.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.2
vs History
91
vs Industry
9
Median 3Y
15.3
Median 5Y
17
Industry
6.6
Forward
13.4
More Details
10.4
EV/OCF
EV/OCF
Enterprise Value to OCF
10.4
vs History
93
vs Industry
13
Median 3Y
13.5
Median 5Y
14.2
Industry
8.8
More Details
12
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
12
vs History
85
vs Industry
9
Median 3Y
18.3
Median 5Y
18.3
Industry
6.8
More Details
3.7
EV/IC
EV/IC
Enterprise Value to IC
3.7
vs History
71
vs Industry
37
Median 3Y
4.1
Median 5Y
4.4
Industry
5.7
More Details

Multiples Across Competitors

Competitors Multiples
Bio-FD&C Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Bio-FD&C Co Ltd
KOSDAQ:251120
126.1B KRW 6.7 17.8 10.2 12.2
IL
Can Fite Biopharma Ltd
TASE:CANF
154.5T ILS 56 126 368 -3 854 397.8 -3 782 344.2 -3 773 924.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 079 720.5 -161 975.9 -196 690.4 -194 445.9
US
Abbvie Inc
NYSE:ABBV
390.1B USD 6.5 166.2 16.1 22.9
US
Amgen Inc
NASDAQ:AMGN
174.5B USD 4.9 24.9 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
151.2B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.5B USD 9.9 31.4 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.2 -527.5 -574.4 -559.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.9B USD 5.6 17.5 16.6 18.9
AU
CSL Ltd
ASX:CSL
83.9B AUD 3.6 18.7 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD 15.2 1 119.2 150.8 182.9
P/S Multiple
Revenue Growth P/S to Growth
KR
B
Bio-FD&C Co Ltd
KOSDAQ:251120
Average P/S: 8 200 746.7
6.7
19%
0.4
IL
C
Can Fite Biopharma Ltd
TASE:CANF
56 126 368
140%
400 902.6
FR
Pharnext SCA
OTC:PNEXF
34 079 720.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 067.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.2
46%
0.3
P/E Multiple
Earnings Growth PEG
KR
B
Bio-FD&C Co Ltd
KOSDAQ:251120
Average P/E: 176.8
17.8
29%
0.6
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 854 397.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 975.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
10%
1.7
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 119.2
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
B
Bio-FD&C Co Ltd
KOSDAQ:251120
Average EV/EBITDA: 32.5
10.2
22%
0.5
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 782 344.2 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 690.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
150.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
B
Bio-FD&C Co Ltd
KOSDAQ:251120
Average EV/EBIT: 38.4
12.2
26%
0.5
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 773 924.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 445.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
182.9
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.